MP58-12 LESS MORTALITY AND LESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) UNDER LONG-TERM TESTOSTERONE THERAPY (TTh): 15-YEAR DATA FROM A PROSPECTIVE CONTROLLED REGISTRY STUDY (2021)

You have accessJournal of UrologyHealth Services Research: Quality Improvement & Patient Safety IV (MP58)1 Sep 2021MP58-12 LESS MORTALITY AND LESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) UNDER LONG-TERM TESTOSTERONE THERAPY (TTh): 15-YEAR DATA FROM A PROSPECTIVE CONTROLLED REGISTRY STUDY Ahmad Al-Qudimat, Mustafa Alwani, Raed M. Al-Zoubi, Khalid Al-Rumaihi, Raidh Talib, Karim Haider, and Farid Saad Ahmad Al-QudimatAhmad Al-Qudimat More articles by this author , Mustafa AlwaniMustafa Alwani More articles by this author , Raed M. Al-ZoubiRaed M. Al-Zoubi More articles by this author , Khalid Al-RumaihiKhalid Al-Rumaihi More articles by this author , Raidh TalibRaidh Talib More articles by this author , Karim HaiderKarim Haider More articles by this author , and Farid SaadFarid Saad More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002088.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We have previously demonstrated improvements in cardiometabolic risk factors in hypogonadal men on long-term TTh. METHODS: Cumulative registry study to investigate long-term effectiveness and safety of 3-monthly TU to treat hypogonadism was established in 2004 in a urological setting. Of 805 hypogonadal men, 412 received parenteral TU 1000 mg/12 weeks (T-group) for up to 12 years. 393 men opted against TTh and served as controls (CTRL). 10-year data are reported. Confounders including age, BMI, smoking, alcohol, total and HDL cholesterol, systolic blood pressure and type 2 diabetes were assessed and considered in statistical modelling. RESULTS: Baseline age was 57.7±7.4 in the T-group and 63.7±4.8 years in CTRL (p <0.001). The absolute follow-up time comprised approximately 6.500 patient-years. The mean Framingham risk score at baseline was 15.5 in the T-group and 15.8 in CTRL (p <0.05). The mean 10-year risk was 22.7% in the T-group and 23.5% in CTRL (p=0.11). Mean and median observation time in the T-group was 8 years. There were 16 deaths (3.9%) but no myocardial infarctions or strokes. Mean observation time in CTRL was 8, median 9 years. There were 74 deaths (18.8%), 70 MIs (17.8%) and 59 strokes (15%). All classical cardiovascular risk factors including obesity, glycaemic control, lipid pattern, and C-reactive protein improved in the T-group and worsened in CTRL. The reduction of cardiovascular events by TTh after applying a linear mixed effect model was 24.7% and 15.5% after applying a random effect longitudinal model. CONCLUSIONS: In hypogonadal men, long-term (TTh) reduces cardiovascular events and mortality. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e992-e993 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ahmad Al-Qudimat More articles by this author Mustafa Alwani More articles by this author Raed M. Al-Zoubi More articles by this author Khalid Al-Rumaihi More articles by this author Raidh Talib More articles by this author Karim Haider More articles by this author Farid Saad More articles by this author Expand All Advertisement PDF downloadLoading ...